TD Cowen analyst Michael Nedelcovych raised the firm’s price target on Novo Nordisk to $115 from $105 and keeps an Outperform rating on the shares. The firm said revenue and earnings growth should outpace most peers with upside possible. There are several catalysts expected in the next 1-2 years, some of which may be underappreciated. Combined with a promising pipeline and creative management team expanding efforts in CVD and NASH, Cowen views Nov Vordisk as deserving of its premium valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Elastic upgraded, Alibaba downgraded: Wall Street’s top analyst calls
- Novo Nordisk price target raised to $115 from $110 at Argus
- ‘Impressive’ Altimmune data likely drives strategic interest, says B. Riley
- Cantor starts Novo Nordisk with Overweight on obesity growth runway
- Novo Nordisk initiated with an Overweight at Cantor Fitzgerald